An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression

Vaccine

Volumn 34, Issue 18, 2016, Pages 2147-2156

  Ragonnaud, Emeline ^a   Andersson, Anne Marie C ^a   Pedersen, Anders Elm ^a   Laursen, Henriette ^a   Holst, Peter J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

4 1BBL; Adenoviral vectors; Cancer; Costimulation; T cells; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; FIBROBLAST; IMMUNE RESPONSE; INFLUENZA A; LONG TERM SURVIVAL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION; WESTERN BLOTTING; ADENOVIRIDAE; ANIMAL; C57BL MOUSE; COS CELL LINE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM;

4-1BB LIGAND; ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD137; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COS CELLS; FEMALE; FIBROBLASTS; HEK293 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 84962590233     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.087     Document Type: Article

References (42)

1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489. (Dec 22).
2. Krieg C., Letourneau S., Pantaleo G., Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010, 107(26):11906-11911. (Jun 29).
3. Coventry B.J., Ashdown M.L. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 2012, 4:215-221.
4. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515(7528):563-567. (Nov 27).
5. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4 PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014, 2:3.
6. Holst P.J., Sorensen M.R., Mandrup Jensen C.M., Orskov C., Thomsen A.R., Christensen J.P. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 2008, 180(5):3339-3346. (Mar 1).
7. Sorensen M.R., Holst P.J., Pircher H., Christensen J.P., Thomsen A.R. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 2009, 39(10 (Oct)):2725-2736.
8. Sorensen M.R., Holst P.J., Steffensen M.A., Christensen J.P., Thomsen A.R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010, 28(41):6757-6764. (Sep 24).
9. Jensen B.A., Steffensen M.A., Nielsen K.N., Christensen J.P., Thomsen A.R., Holst P.J. Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination. Mol Ther 2014, 22(12 (Dec)):2107-2117.
10. Vonderheide R.H., Flaherty K.T., Khalil M., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007, 25(7):876-883. (Mar 1).
11. Goodwin R.G., Din W.S., Davis-Smith T., et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993, 23(10 (Oct)):2631-2641.
12. Futagawa T., Akiba H., Kodama T., et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002, 14(3 (Mar)):275-286.
13. Cheuk A.T., Mufti G.J., Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004, 11(3 (Mar)):215-226.
14. Pollok K.E., Kim Y.J., Zhou Z., et al. Inducible T cell antigen 4-1BB analysis of expression and function. J Immunol 1993, 150(3):771-781. (Feb 1).
15. Kwon B.S., Kestler D.P., Eshhar Z., Oh K.O., Wakulchik M. Expression characteristics of two potential T cell mediator genes. Cell Immunol 1989, 121(2 (Jul)):414-422.
16. Cannons J.L., Lau P., Ghumman B., et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001, 167(3):1313-1324. (Aug 1).
17. Spencer A.J., Furze J., Honeycutt J.D., et al. 4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques. PLoS One 2014, 9(8):e105520.
18. Shuford W.W., Klussman K., Tritchler D.D., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186(1):47-55. (Jul 7).
19. Diehl L., van Mierlo G.J., den Boer A.T., et al. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 2002, 168(8):3755-3762. (Apr 15).
20. Wen T., Bukczynski J., Watts T.H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002, 168(10):4897-4906. (May 15).
21. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11(5 (May)):1062-1070.
22. Melero I., Shuford W.W., Newby S.A., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3(6 (Jun)):682-685.
23. Huang J.H., Zhang S.N., Choi K.J., et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010, 18(2 (Feb)):264-274.
24. Jensen B.A., Pedersen S.R., Christensen J.P., Thomsen A.R. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One 2013, 8(6):e66081.
25. Niu L., Strahotin S., Hewes B., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007, 178(7):4194-4213. (Apr 1).
26. Moraes T.J., Lin G.H., Wen T., Watts T.H. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease. Vaccine 2011, 29(37):6301-6312. (Aug 26).
27. Janik P., Briand P., Hartmann N.R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 1975, 35(12 (Dec)):3698-3704.
28. Bang B.R., Kim S.J., Yagita H., Croft M., Kang Y.J. Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice. Eur J Immunol 2015, 45(3 (Mar)):886-892.
29. Jorgensen T.N., Haase C., Michelsen B.K. Treatment of an immortalized APC cell line with both cytokines and LPS ensures effective T-cell activation in vitro. Scand J Immunol 2002, 56(5 (Nov)):492-503.
30. Mendoza L., Bubenik J., Simova J., Jandlova T., Vonka V., Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003, 23(1 (Jul)):243-247.
31. Grujic M., Bartholdy C., Remy M., Pinschewer D.D., Christensen J.P., Thomsen A.R. The role of CD80/CD86 in generation and maintenance of functional virus-specific CD8+ T cells in mice infected with lymphocytic choriomeningitis virus. J Immunol 2010, 185(3):1730-1743. (Aug 1).
32. Steffensen M.A., Holst P.J., Steengaard S.S., et al. Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation. J Virol 2013, 87(11 (Jun)):6283-6295.
33. Xu D.P., Sauter B.V., Huang T.G., Meseck M., Woo S.L., Chen S.H. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 2005, 12(20 (Oct)):1526-1533.
34. Wyzgol A., Muller N., Fick A., et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009, 183(3):1851-1861. (Aug 1).
35. Holst P.J., Jensen B.A., Ragonnaud E., Thomsen A.R., Christensen J.P. Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection. PLoS One 2015, 10(2):e0117242.
36. Cui W., Kaech S.M. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 2010, 236 (Jul):151-166.
37. Ahlers J.D., Belyakov I.M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010, 115(9):1678-1689. (Mar 4).
38. Macdonald D.C., Hotblack A., Akbar S., Britton G., Collins M.K., Rosenberg W.C. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans. J Immunol 2014, 193(10):5056-5064. (Nov 15).
39. Holst P.J., Orskov C., Thomsen A.R., Christensen J.P. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010, 184(8):4431-4439. (Apr 15).
40. Gauttier V., Judor J.P., Le G.V., Cany J., Ferry N., Conchon S. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer 2014, 135(12):2857-2867. (Dec 15).
41. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181(8):5791-5802. (Oct 15).
42. Lechner M.G., Megiel C., Russell S.M., et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011, 9:90.